A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers-Reference-Cited by-同舟云学术

A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers

Published:2017-01 Issue:1 Volume:32 Page:e2569
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum. Psychopharmacol Clin Exp

Author:

Boland Katja¹,Moschetti Viktoria²,Dansirikul Chantaratsamon¹,Pichereau Solen¹,Gheyle Lien³,Runge Frank¹,Zimdahl-Gelling Heike¹,Sand Michael⁴

Affiliation:

1. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach an der Riss Germany

2. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim am Rhein Germany

3. Clinical Research; SGS, Life Science Services; Antwerpen Belgium

4. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology

Reference23 articles.

1. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease;Bonkale;Neuroscience Letters,1995

2. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 409306 filmcoated tablets given orally qd for 14 days in patients with schizophrenia. International Congress on Schizophrenia Research;Brown;Schizophrenia Bulletin,2015

3. BI 409306, a novel phosphodiesterase 9A inhibitor, part I: Potency, selectivity and in-vitro functional characterization on synaptic plasticity. International Congress on Schizophrenia Research;Dorner-Ciossek;Schizophrenia Bulletin,2015

4. Phosphodiesterases as therapeutic targets for Alzheimer's disease;García-Osta;ACS Chemical Neuroscience,2012

5. Low CSF concentrations of cyclic GMP in schizophrenia;Gattaz;The British Journal of Psychiatry,1983

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies;British Journal of Clinical Pharmacology;2024-06-16

2. Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases;European Journal of Medicinal Chemistry;2024-05

3. An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential;European Journal of Medicinal Chemistry;2023-11

4. The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study;European Journal of Clinical Pharmacology;2022-01-28

5. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics;Neuroscience & Biobehavioral Reviews;2022-01